Efficacy of Statins with Ezetimibe and Bempedoic Acid in Achieving Target LDL Levels in Post MI Patients

Dyslipidaemia is a major risk factor in the progression of Myocardial Infarction. So, we need to pay closer attention to achieving desired Lipid levels in MI patients to prevent progression to Congestive Heart Failure. The study was conducted in Cardiology In-Patient and Out-Patient departments after the approval of the Ethical Committee. Patients were selected based on the inclusion and exclusion criteria. Patients were divided into 3 groups. Group 1 served as Control group patients who were treated with Statins. Group 2 patients were treated with Statin+ Ezetimibe and Group 3 patients were treated with Statins + Bempedoic acid. The clinical efficacy of the drugs given in our study period was analysed based on the data collected from Groups 1, 2 and 3. The three therapies--statin, combination of statin and bempedoic acid, and a combination of statin and ezetimibe were given to the patients who had signed up. The results showed that for a period of three months, Statin + Bempedoic acid therapy and Statin + Ezetimibe combination therapy had better efficacy in achieving target LDL levels in comparison to Statin monotherapy. We conclude that among both combination therapies, Statin + Ezetimibe therapy has shown the most efficacy in achieving target LDL levels in post MI patients.